Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 2 of 2 results for sucroferric oxyhydroxide

  1. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.

    NICE guideline
    Last updated
    24 November 2021
    View recommendations

    Sections for NG203

  2. Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

    This evidence summary has been updated and replaced by NICE guideline NG203.

    Evidence summary
    Published
    6 January 2015